Inflammation is a critical factor in the pain and cartilage breakdown associated with knee and hip osteoarthritis. One mechanism of knee OA progression is a degenerative feed-forward cycle caused by pathological increases in inflammatory cytokines and catabolic factors within and adjacent to the synovial space. Inflammatory and catabolic proteins such as interleukin-1 beta (IL-1β), tumor necrosis factor alpha (TNFα), and matrix metalloproteinases (MMPs), for example, have been implicated in cartilage degradation and continued OA progression. Approaches to block these deleterious proteins could improve patients’ symptoms, and perhaps the progression of the disease may be halted or even reversed. Autologous blood contains a host of proteins, which can block the action or production of inflammatory and catabolic proteins. Anti-inflammatory cytokines in blood include interleukin-1 receptor antagonist (IL-1ra), soluble interleukin-1 receptor type I (sIL-RI), soluble tumor necrosis factor receptor-type I (sTNF-RI), and soluble tumor necrosis factor receptor-type II (sTNF-RII). Likewise, anabolic growth factors from platelets and blood plasma, such as transforming growth factor beta (TGF-β) and insulin-like growth factor-1 (IGF-1), are also present in systemic blood. A strategy to overcome the pathologically high levels of proinflammatory and catabolic proteins, which contribute to OA, would be to introduce highly concentrated amounts of anti-inflammatory and anabolic proteins into the arthritic joint.

Advanced autologous therapies are on the rise in medicine due to their ability to be tailored at the molecular level. They can be tailored to address specific injuries and diseases, such as osteoarthritis, by targeting inflamed cytokines. These inflamed cytokines are the cause of OA pain and cartilage degeneration. IRAP (Autologous Protein Concentrate) is one autologous therapy we now offer to treat OA of the knee and hip. The IRAP solution contains a unique profile of your own concentrated white blood cells, platelets, and plasma. Recent studies have concluded that these concentrated elements in APC allow for the solution to inhibit inflammation and reduce cartilage degradation.

The Growth Factor approach:

  • Significantly reduces pain
  • Significantly increases function
  • Stimulates cell proliferation
  • Blocks cartilage destruction
  • Slows cartilage degradation

Growth Factors are also found in the bone marrow along with Adult Mesenchymal Stem Cells and Platelets. By concentrating blood and bone marrow, I am able to deliver a highly concentrated volume of stem cells, progenitor cells, platelets and growth factors to the joint harnessing your body’s biologic potential.

We have the ability to provide the right solution for each individual patient. You may schedule a consultation by calling my office   312 475 1893

To view my website and watch my webinar go to    www.ilcellulartherapy.com